Quality of life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second line therapy: a multicener prospective observational study

Conclusion The QOL among patients on nilotinib administered as a second-line therapy was very good and adherence to the treatment was high. The efficacy and safety of the drug were confirmed in the real-life setting. Teaser To evaluate quality-of-life (QOL) and adherence to Nilotinib used as a second line therapy in 177 chronic myeloid leukemia patients in chronic phase a multicenter, prospective observational study was conducted. The QOL was very good and adherence to the treatment was high. Study results could be taken into consideration in the process of TKI treatment choice
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research